2 news items
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
AKBA
9 May 24
to patients as we remain committed to the kidney community. We also expect to engage with the FDA on label expansion opportunities for Vafseo by the end
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
AKBA
27 Mar 24
John P. Butler, Chief Executive Officer of Akebia. "At Akebia we are committed to kidney patients, a dedication that has
- Prev
- 1
- Next